These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 1701780)
1. Selective in vivo inhibition of T cell activation by class II MHC-binding peptides administered in soluble form. Muller S; Adorini L; Juretic A; Nagy ZA J Immunol; 1990 Dec; 145(12):4006-11. PubMed ID: 1701780 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of T cell response with peptides is influenced by both peptide-binding specificity of major histocompatibility complex molecules and susceptibility of T cells to blocking. Lehmann PV; Cardinaux F; Appella E; Muller S; Falcioni F; Adorini L; Nagy ZA Eur J Immunol; 1989 Jun; 19(6):1071-7. PubMed ID: 2787751 [TBL] [Abstract][Full Text] [Related]
3. Induction of class II major histocompatibility complex blockade as well as T cell tolerance by peptides administered in soluble form. Nihira SI; Falcioni F; Juretic A; Bolin D; Nagy ZA Eur J Immunol; 1996 Aug; 26(8):1736-42. PubMed ID: 8765014 [TBL] [Abstract][Full Text] [Related]
4. Co-dominant restriction by a mixed-haplotype I-A molecule (alpha k beta b) for the lysozyme peptide 52-61 in H-2k x H-2b F1 mice. Moreno J; Adorini L; Hämmerling GJ J Immunol; 1990 May; 144(9):3296-304. PubMed ID: 1970351 [TBL] [Abstract][Full Text] [Related]
5. Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells. Leighton J; Sette A; Sidney J; Appella E; Ehrhardt C; Fuchs S; Adorini L J Immunol; 1991 Jul; 147(1):198-204. PubMed ID: 1711074 [TBL] [Abstract][Full Text] [Related]
6. Limited T cell response to donor MHC peptides during allograft rejection. Implications for selective immune therapy in transplantation. Benichou G; Fedoseyeva E; Lehmann PV; Olson CA; Geysen HM; McMillan M; Sercarz EE J Immunol; 1994 Aug; 153(3):938-45. PubMed ID: 7517977 [TBL] [Abstract][Full Text] [Related]
7. Cathepsin D, but not cathepsin B, releases T cell stimulatory fragments from lysozyme that are functional in the context of multiple murine class II MHC molecules. van Noort JM; Jacobs MJ Eur J Immunol; 1994 Sep; 24(9):2175-80. PubMed ID: 8088334 [TBL] [Abstract][Full Text] [Related]
8. In vivo competition between self peptides and foreign antigens in T-cell activation. Adorini L; Muller S; Cardinaux F; Lehmann PV; Falcioni F; Nagy ZA Nature; 1988 Aug; 334(6183):623-5. PubMed ID: 3261393 [TBL] [Abstract][Full Text] [Related]
9. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of experimental autoimmune encephalomyelitis by MHC class II binding competitor peptides depends on the relative MHC binding affinity of the disease-inducing peptide. Wauben MH; Joosten I; Schlief A; van der Zee R; Boog CJ; van Eden W J Immunol; 1994 Apr; 152(8):4211-20. PubMed ID: 7511673 [TBL] [Abstract][Full Text] [Related]
11. Functional mapping of MHC class II polymorphic residues. The alpha-chain controls the specificity for binding an Ad-versus an A k-restricted peptide and the beta-chain region 65-67 controls T cell recognition but not peptide binding. Lee JM; McKean DJ; Watts TH J Immunol; 1991 May; 146(9):2952-9. PubMed ID: 1849939 [TBL] [Abstract][Full Text] [Related]
12. Modulation of restricted class II T cell responses by peptides derived from self class II molecule. Li WF; Fan MD; Pan CB; Gefter ML; Lai MZ Eur J Immunol; 1992 Oct; 22(10):2527-31. PubMed ID: 1396959 [TBL] [Abstract][Full Text] [Related]
13. T cell epitope selection: dominance may be determined by both affinity for major histocompatibility complex and stoichiometry of epitope. Li WF; Fan MD; Pan CB; Lai MZ Eur J Immunol; 1992 Apr; 22(4):943-9. PubMed ID: 1372561 [TBL] [Abstract][Full Text] [Related]
14. Distinction between immunogenicity and tolerogenicity among HBcAg T cell determinants. Influence of peptide-MHC interaction. Milich DR; Jones JE; McLachlan A; Houghten R; Thornton GB; Hughes JL J Immunol; 1989 Nov; 143(10):3148-56. PubMed ID: 2478619 [TBL] [Abstract][Full Text] [Related]
15. Interference with the binding of a naturally processed peptide to class II alters the immunodominance of T cell epitopes in vivo. Nikcevich KM; Kopielski D; Finnegan A J Immunol; 1994 Aug; 153(3):1015-26. PubMed ID: 7517970 [TBL] [Abstract][Full Text] [Related]
16. Processing of endogenously synthesized hen egg-white lysozyme retained in the endoplasmic reticulum or in secretory form gives rise to a similar but not identical set of epitopes recognized by class II-restricted T cells. Adorini L; Guéry JC; Fuchs S; Ortiz-Navarrete V; Hämmerling GJ; Momburg F J Immunol; 1993 Oct; 151(7):3576-86. PubMed ID: 7690807 [TBL] [Abstract][Full Text] [Related]
17. Constitutive presentation of dominant epitopes from endogenous naturally processed self-beta 2-microglobulin to class II-restricted T cells leads to self-tolerance. Guéry JC; Sette A; Appella E; Adorini L J Immunol; 1995 Jan; 154(2):545-54. PubMed ID: 7814867 [TBL] [Abstract][Full Text] [Related]
18. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo. Shen X; Hu B; McPhie P; Wu X; Fox A; Germain RN; König R J Immunol; 1996 Jul; 157(1):87-100. PubMed ID: 8683160 [TBL] [Abstract][Full Text] [Related]
19. Immunodominance does not result from peptide competition for MHC class II presentation. Lo-Man R; Langeveld JP; Martineau P; Hofnung M; Meloen RH; Leclerc C J Immunol; 1998 Feb; 160(4):1759-66. PubMed ID: 9469434 [TBL] [Abstract][Full Text] [Related]
20. Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells. Adorini L; Ullrich SJ; Appella E; Fuchs S Nature; 1990 Jul; 346(6279):63-6. PubMed ID: 2366863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]